Aligos Therapeutics, Inc. (NASDAQ:ALGS – Get Free Report) shares were up 4.9% during mid-day trading on Wednesday . The company traded as high as $7.84 and last traded at $7.68. Approximately 19,208 shares were traded during trading, a decline of 35% from the average daily volume of 29,566 shares. The stock had previously closed at $7.32.
Analyst Upgrades and Downgrades
Separately, HC Wainwright restated a “buy” rating and issued a $75.00 target price on shares of Aligos Therapeutics in a research note on Friday, September 20th.
Check Out Our Latest Report on Aligos Therapeutics
Aligos Therapeutics Trading Up 10.6 %
Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of ($4.00) by $4.75. Aligos Therapeutics had a negative return on equity of 110.59% and a negative net margin of 1,100.48%. The firm had revenue of $1.06 million during the quarter. During the same period in the prior year, the company posted ($10.75) EPS. On average, analysts forecast that Aligos Therapeutics, Inc. will post -8.2 EPS for the current year.
Institutional Investors Weigh In On Aligos Therapeutics
Institutional investors have recently modified their holdings of the stock. Opaleye Management Inc. bought a new stake in shares of Aligos Therapeutics in the 4th quarter valued at approximately $861,000. Acadian Asset Management LLC boosted its holdings in Aligos Therapeutics by 17.6% in the first quarter. Acadian Asset Management LLC now owns 657,995 shares of the company’s stock worth $644,000 after purchasing an additional 98,628 shares during the period. Finally, Armistice Capital LLC raised its holdings in shares of Aligos Therapeutics by 5.3% during the second quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock worth $2,540,000 after purchasing an additional 363,000 shares during the period. Institutional investors and hedge funds own 60.43% of the company’s stock.
About Aligos Therapeutics
Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).
Recommended Stories
- Five stocks we like better than Aligos Therapeutics
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- Do ETFs Pay Dividends? What You Need to Know
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- ETF Screener: Uses and Step-by-Step Guide
- 4 Quirky ETFs With Big Potential for Impressive Gains
Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.